/주식/JAZZ
JAZZ

JAZZ

USD

Jazz Pharmaceuticals plc Common Stock (Ireland)

$109.615-1.330 (-1.199%)

실시간 가격

Healthcare
생명공학
아일랜드

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$110.945

고가

$111.450

저가

$109.480

거래량

0.48M

기업 기본 정보

시가총액

6.6B

산업

생명공학

국가

Ireland

거래 통계

평균 거래량

1.27M

거래소

NMS

통화

USD

52주 범위

저가 $95.49현재가 $109.615고가 $148.06

관련 뉴스

Analyst Upgrades

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $202 price target.

더 보기
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
PR Newswire

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...

더 보기
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
PR Newswire

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium,...

더 보기
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
Analyst Upgrades

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $202 price target.

더 보기
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
PR Newswire

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 IMforte study of Zepzelca® (lurbinectedin) in combination...

더 보기
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
PR Newswire

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2...

PR Newswire

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP...